A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
The high-affinity IgE receptor (FcεRI) on mast cells and basophils binds IgE with extraordinary affinity, allowing these cells to remain armed with IgE for extended periods. Cross-linking of FcεRI by allergen-IgE complexes triggers rapid degranulation and release of histamine, tryptase, and inflammatory mediators within seconds, initiating type I hypersensitivity reactions.
Examine the molecular events in FcεRI signaling, from receptor aggregation through calcium mobilization and granule exocytosis. Consider how antihistamines and mast cell stabilizers interfere with this pathway.
FcεRI binding does not trigger mast cell activation by itself; crosslinking by bivalent allergen is required. IgE can remain bound to FcεRI for months without causing degranulation.
From antibody structure, you know that immunoglobulins have a variable region that binds antigen and a constant (Fc) region that determines effector function — which immune cells respond and how. From type I hypersensitivity, you know that allergic reactions involve IgE antibodies and the rapid release of inflammatory mediators. This topic zooms into the molecular mechanism at the center of that process: how the high-affinity IgE receptor (FcεRI) on mast cells converts allergen exposure into the explosive degranulation response that produces allergic symptoms within seconds.
FcεRI is unusual among Fc receptors because of its extraordinarily high affinity for its antibody — roughly 100 to 1,000 times higher than most other Fc receptor-antibody interactions. This means that IgE binds FcεRI essentially irreversibly under physiological conditions. Mast cells and basophils become pre-armed with IgE: even in the absence of allergen, free IgE molecules in the blood bind to FcεRI and remain attached for weeks to months. The mast cell sits in tissues — especially at mucosal surfaces, near blood vessels, and in the skin — decorated with thousands of IgE molecules, each one a loaded sensor waiting for its specific allergen. Importantly, this binding alone does nothing. A single IgE molecule sitting on a single FcεRI does not activate the cell.
Activation requires cross-linking: a multivalent allergen (a pollen protein, a food allergen, a drug hapten) must bind to two or more IgE molecules simultaneously, physically pulling their FcεRI receptors together on the cell surface. This receptor aggregation is the critical trigger. When FcεRI molecules cluster, their cytoplasmic tails — specifically the ITAM (immunoreceptor tyrosine-based activation motif) sequences on the β and γ chains — are phosphorylated by the Src-family kinase Lyn. This initiates a signaling cascade through the kinase Syk, which activates phospholipase C, producing IP3 and diacylglycerol. IP3 triggers calcium release from intracellular stores, and the resulting calcium surge drives the fusion of preformed granules with the plasma membrane — degranulation. Within seconds, histamine, heparin, tryptase, and other preformed mediators flood the surrounding tissue.
The signaling cascade also activates a slower but sustained response: phospholipase A2 generates arachidonic acid, which is converted into prostaglandins and leukotrienes — lipid mediators that cause prolonged bronchoconstriction, vasodilation, and mucus secretion. Meanwhile, NF-κB activation drives transcription of inflammatory cytokines (TNF-α, IL-4, IL-13) that recruit other immune cells and sustain the late-phase allergic response hours after the initial degranulation. Understanding this two-phase response — immediate degranulation followed by de novo mediator synthesis — explains why allergic reactions can persist and worsen over time, and why therapeutic strategies target multiple points in the pathway: antihistamines block histamine receptors, mast cell stabilizers (like cromolyn) prevent degranulation, leukotriene inhibitors block lipid mediators, and anti-IgE antibodies (omalizumab) intercept free IgE before it can arm mast cells.